In an effort to identify therapeutic targets in MPTs, research with limited series has discovered potentially actionable mutations in the RTK/RAS/RAF (NF1, EGFR, BRAF, NRAS) and PI3K/AKT/mTOR (PIK3CA, PTEN, STK11) pathways13-25; and while there are US Food and Drug Administration (FDA)-approved therapies available in other tumor types, these have never been tested in MPTs. This evidence concerns the gene NRAS and neoplasm.